Home Monitoring for Age-Related Macular Degeneration

  • Voraporn Chaikitmongkol


In the anti-vascular endothelial growth factor (anti-VEGF) era, visual outcomes of choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) have been dramatically improved. Good baseline vision and smaller size of CNV at the time of treatment initiation are the main predictors for favorable outcomes. Patients at high risk of developing neovascular AMD are those with intermediate-staged AMD who typically been scheduled for evaluations 1–2 times/year. Home-monitoring devices, therefore, become a potential tool to first detect changes in the visual functions of these patients before their clinic visits. Prompt evaluations following an alert from the device, with timely anti-VEGF treatments would increase the patients’ opportunities to achieve excellent outcomes.

The Amsler grid was the first home-monitoring device for AMD and had been widely used since the 1940s. In the past decade, many home-monitoring devices have been developed, but only two have been approved by the United States Food and Drug Administration, i.e., ForeseeHome device (preferential hyperacuity perimeter) and MyVisionTrack (handheld shape discrimination hyperacuity test). The ForeseeHome device has been the only home-monitoring device evaluated and proven in a large clinical trial, the Home Monitoring of the Eye (HOME) study. Results suggested that participants in the device arm had a lesser degree of vision loss from baseline vision at the time of CNV detection. Despite its proven efficacy, the ForeseeHome device is currently available only in the United States. Several other home-monitoring technologies on personal electronic devices have been introduced, but strong evidence to support the validity of these technologies in detecting CNV is still limited.


Age-related macular degeneration Choroidal neovascularization Early detection Home monitoring Preferential hyperacuity perimeter Shape discrimination hyperacuity Self-monitoring 


  1. 1.
    Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014 Feb;2(2):e106–16.PubMedGoogle Scholar
  2. 2.
    Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419–31.PubMedCrossRefGoogle Scholar
  3. 3.
    Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009 Jan;116(1):57–65.e5.PubMedCrossRefGoogle Scholar
  4. 4.
    Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014 Jan;121(1):193–201.PubMedCrossRefGoogle Scholar
  5. 5.
    Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying G, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012 Jul;119(7):1388–98.CrossRefGoogle Scholar
  6. 6.
    Ying G, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013 Jan;120(1):122–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Ying G, Maguire MG, Daniel E, Ferris FL, Jaffe GJ, Grunwald JE, et al. Association of baseline Characteristics and early vision response with 2-year vision outcomes in the comparison of AMD treatments trials (CATT). Ophthalmology. 2015 Dec;122(12):2523–2531.e1.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003 Sep;136(3):407–18.PubMedCrossRefGoogle Scholar
  9. 9.
    Lim JH, Wickremasinghe SS, Xie J, Chauhan DS, Baird PN, Robman LD, et al. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol. 2012 Apr;153(4):678–686.e2.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Marmor MF. A brief history of macular grids: from Thomas Reid to Edvard Munch and Marc Amsler. Surv Ophthalmol. 2000 Feb;44(4):343–53.PubMedCrossRefGoogle Scholar
  11. 11.
    Amsler M. Earliest symptoms of diseases of the macula. Br J Ophthalmol. 1953 Sep;37(9):521–37.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Fine AM, Elman MJ, Ebert JE, Prestia PA, Starr JS, Fine SL. Earliest symptoms caused by neovascular membranes in the macula. Arch Ophthalmol. 1986 Apr;104(4):513–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Schuchard RA. Validity and interpretation of Amsler grid reports. Arch Ophthalmol. 1993 Jun;111(6):776–80.PubMedCrossRefGoogle Scholar
  14. 14.
    Achard OA, Safran AB, Duret FC, Ragama E. Role of the completion phenomenon in the evaluation of Amsler grid results. Am J Ophthalmol. 1995 Sep;120(3):322–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Augustin AJ, Offermann I, Lutz J, Schmidt-Erfurth U, Tornambe P. Comparison of the original Amsler grid with the modified Amsler grid: result for patients with age-related macular degeneration. Retina Phila Pa. 2005 Jun;25(4):443–5.CrossRefGoogle Scholar
  16. 16.
    Faes L, Bodmer NS, Bachmann LM, Thiel MA, Schmid MK. Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis. Eye. 2014 Jul;28(7):788–96.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Goldstein M, Loewenstein A, Barak A, Pollack A, Bukelman A, Katz H, et al. Results of a multicenter clinical trial to evaluate the preferential hyperacuity perimeter for detection of age-related macular degeneration. Retina Phila Pa. 2005 May;25(3):296–303.CrossRefGoogle Scholar
  18. 18.
    Preferential Hyperacuity Perimetry Research Group. Preferential hyperacuity perimeter (PreView PHP) for detecting choroidal neovascularization study. Ophthalmology. 2005 Oct;112(10):1758–65.CrossRefGoogle Scholar
  19. 19.
    Loewenstein A, Ferencz JR, Lang Y, Yeshurun I, Pollack A, Siegal R, et al. Toward earlier detection of choroidal neovascularization secondary to age-related macular degeneration: multicenter evaluation of a preferential hyperacuity perimeter designed as a home device. Retina Phila Pa. 2010 Aug;30(7):1058–64.CrossRefGoogle Scholar
  20. 20.
    Chew EY, Clemons TE, Bressler SB, Elman MJ, Danis RP, Domalpally A, et al. Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The home monitoring of the eye (HOME) study design – HOME study report number 1. Contemp Clin Trials. 2014 Mar;37(2):294–300.PubMedCrossRefGoogle Scholar
  21. 21.
    Chew EY, Clemons TE, Bressler SB, Elman MJ, Danis RP, Domalpally A, et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the eye (HOME) study. Ophthalmology. 2014 Feb;121(2):535–44.PubMedCrossRefGoogle Scholar
  22. 22.
    Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA. 2013 May 15;309(19):2005–15.CrossRefGoogle Scholar
  23. 23.
    Chaikitmongkol V, Bressler NM, Bressler SB. Early detection of choroidal neovascularization facilitated with a home monitoring program in age-related macular degeneration. Retin Cases Brief Rep. 2015;9(1):33–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Wilkinson F, Wilson HR, Habak C. Detection and recognition of radial frequency patterns. Vis Res. 1998 Nov;38(22):3555–68.PubMedCrossRefGoogle Scholar
  25. 25.
    Wang Y-Z, Wilson E, Locke KG, Edwards AO. Shape discrimination in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2002 Jun;43(6):2055–62.PubMedGoogle Scholar
  26. 26.
    Wang YZ. Effects of aging on shape discrimination. Optom Vis Sci Off Publ Am Acad Optom. 2001 Jun;78(6):447–54.CrossRefGoogle Scholar
  27. 27.
    Wang Y-Z, He Y-G, Mitzel G, Zhang S, Bartlett M. Handheld shape discrimination hyperacuity test on a mobile device for remote monitoring of visual function in maculopathy. Invest Ophthalmol Vis Sci. 2013 Aug 13;54(8):5497–505.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Kaiser PK, Wang Y-Z, He Y-G, Weisberger A, Wolf S, Smith CH. Feasibility of a novel remote daily monitoring system for age-related macular degeneration using mobile handheld devices: results of a pilot study. Retina Phila. 2013 Oct;33(9):1863–70.CrossRefGoogle Scholar
  29. 29.
    Chen JS, Adelman RA. Hyperacuity exam screens for choroidal neovascularization in age-related macular degeneration on a mobile device. Ophthalmic Surg Lasers Imaging Retina. 2016;47(8):708–15.PubMedCrossRefGoogle Scholar
  30. 30.
    Adams M, Ho CYD, Baglin E, Sharangan P, Wu Z, Lawson DJ, et al. Home monitoring of retinal sensitivity on a tablet device in intermediate age-related macular degeneration. Transl Vis Sci Technol. 2018 Sep;7(5):32.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Wu Z, Guymer RH, Jung CJ, Goh JK, Ayton LN, Luu CD, et al. Measurement of retinal sensitivity on tablet devices in age-related macular degeneration. Transl Vis Sci Technol. 2015 Jun;4(3):13.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Ho CYD, Wu Z, Turpin A, Lawson DJ, Luu CD, McKendrick AM, et al. A tablet-based retinal function test in Neovascular age-related macular degeneration eyes and at-risk fellow eye. Transl Vis Sci Technol. 2018 Mar;7(2):2.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Mansour AM. Self-optical coherence tomography and angiography. Case Rep Ophthalmol. 2017 Apr;8(1):108–15.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Maloca P, Hasler PW, Barthelmes D, Arnold P, Matthias M, Scholl HPN, et al. Safety and feasibility of a novel sparse optical coherence tomography device for patient-delivered retina home monitoring. Transl Vis Sci Technol. 2018 Jul;7(4):8.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Voraporn Chaikitmongkol
    • 1
  1. 1.Retina Division, Department of OphthalmologyChiang Mai UniversityChiang MaiThailand

Personalised recommendations